Abbott Laboratories (ABT)

The global molecular diagnostics market is projected to grow from USD 18.26 billion in 2025 to USD 43.50 billion by 2035, with a CAGR of 9.07%. Growth is driven by increasing demand for early and accurate disease detection, rising prevalence of chronic diseases, and adoption of advanced technologies like PCR and next-generation sequencing. The U.S. market is expected to grow from USD 5.0 billion to USD 8.07 billion during the same period.

GlobeNewswire Inc.•Sns Insider

Apr 3

The global drug screening market is projected to reach USD 20.86 billion by 2031, growing at a CAGR of 16.16%. Chromatography and mass spectrometry technologies dominated with 44.77% market share in 2025. Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and workplace safety initiatives. Market growth is fueled by increasing adoption across workplaces, healthcare settings, and law enforcement, alongside technological advancements in point-of-care testing and rapid detection devices.

GlobeNewswire Inc.•Mordor Intelligence

Apr 3

The Schwab U.S. Dividend Equity ETF (SCHD) completed its annual reconstitution, adding UnitedHealth and Abbott Laboratories while removing AbbVie. These changes increased the fund's healthcare sector allocation from 15.4% to 18.9%, making it the second-largest sector weighting. The new holdings have a higher average dividend growth rate (9.4% vs 8.6%), which should generate more income and potentially higher total returns for investors over time.

The Motley Fool•Matt Dilallo

Mar 30

Major M&A activity continues with Estée Lauder in merger discussions with Puig ($40B), KKR acquiring Nothing Bundt Cakes ($2B+), and Amazon acquiring robotics firm Fauna. Other significant deals include Corebridge-Equitable Holdings merger ($22B), Merck's acquisition of Terns Pharmaceuticals ($6.7B), and Abbott closing its Exact Sciences deal ($21B). Several companies filed for bankruptcy including 23andMe and Applebee's franchisee NRPF.

Benzinga•Caroline Ryan

Mar 27

AbbVie and Bristol Myers Squibb are highlighted as exceptions in the healthcare sector, offering above-average dividend yields and consistent dividend growth. AbbVie, a Dividend King with a 3.4% yield, has successfully transitioned from its blockbuster drug Humira to new treatments Skyrizi and Rinvoq. Bristol Myers Squibb, yielding 4.4%, is navigating patent cliffs through innovation in its oncology portfolio, making both attractive for patient, buy-and-hold dividend investors.

The Motley Fool•Eric Volkman

Mar 24

The article recommends two defensive healthcare stocks for portfolio protection during market uncertainty: Abbott Laboratories, a diversified healthcare company with four business units and a 50+ year dividend growth track record, and Intuitive Surgical, the global leader in robotic surgery with strong competitive advantages through surgeon training and recurring accessory revenue.

The Motley Fool•Adria Cimino

Mar 22

Abbott Laboratories stock has declined 22% following disappointing quarterly results with weak diagnostic and nutrition segments. However, the article argues it presents a buying opportunity due to strong medical device performance (up 12.3%), promising growth prospects in continuous glucose monitoring and structural heart products, a $21 billion acquisition of Exact Sciences to boost diagnostics, and an impressive dividend track record with 54 consecutive years of increases.

The Motley Fool•Prosper Junior Bakiny

Mar 19

The global IV solutions market is projected to grow from USD 13.35 billion in 2025 to USD 29.47 billion by 2035, with a CAGR of 8.24%. Growth is driven by increasing prevalence of chronic diseases, rising hospital admissions, and growing demand for parenteral nutrition and critical care solutions. The U.S. market alone is expected to reach USD 8.39 billion by 2035. North America leads with 40.70% market share, while Asia-Pacific shows the fastest growth at 9.46% CAGR.

GlobeNewswire Inc.•Sns Insider

Mar 13

The article recommends Johnson & Johnson and AbbVie as top dividend stocks for long-term investors. Both companies are Dividend Kings with 50+ years of consecutive dividend increases, diversified product portfolios, and strong track records of navigating patent cliffs through innovation. Johnson & Johnson boasts over 100 years of history and consistent revenue growth, while AbbVie demonstrates resilience with successful product launches like Skyrizi and Rinvoq offsetting patent expirations.

The Motley Fool•Prosper Junior Bakiny

Mar 12

The global personalized nutrition market is projected to grow from $15.79 billion in 2025 to $30.94 billion by 2030 at a 14.4% CAGR. Digital tools and active measurement technologies are the fastest-growing segments, while Asia Pacific emerges as a high-growth regional hub driven by expanding middle class, rising lifestyle diseases, and rapid digital health adoption.

GlobeNewswire Inc.•Marketsandmarkets

Mar 11